B
Bullisch
Bullisch · 25%RIGL
$24.81
Szenariopreis
$51.510
+0.783 (+1.52%)Zum Schluss
Loading chart…
- Hoch
- 51.600
- Eröffnung
- 51.170
- Volumengewichteter Durchschnittskurs
- 51.12
- Volumen
- 159.56K
- Marktkap.
- 1.67B
- Tief
- 50.241
- Umsatz
- 8.16M
- EV/EBITDA, TTM
- 8.00
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
KI-Analyse of Rigel Pharmaceuticals Inc (RIGL)
KaufenRigel Pharmaceuticals Inc is a good buy right now due to its current price of $48.13, which is significantly below the analyst price target of $83. The company has shown robust growth with a 62.71% increase over the past year and a strong gross margin of 89.17% in Q2 2026. The main risk is the recent earnings surprise of -3.3%, which may affect short-term sentiment.
Analystenbewertungen (3)
+0.95% Aufwärtspotenzial
Kaufen
3 Kaufen
0 Halten
0 Verkaufen
Aktuell: 51.51
Tief
38.00
Durchschnitt
52.00
Hoch
71.00
Citi
Kaufen
$83
2026-08-06
Citi
2026-08-06
Kursziel
$83
Kaufen
Citi
Kaufen
$81
2026-05-13
Citi
2026-05-13
Kursziel
$81
Kaufen
Citi
Kaufen
$69
2026-05-07
Citi
2026-05-07
Kursziel
$69
Kaufen
Cantor Fitzgerald
Neutral
$38
2025-11-05
Cantor Fitzgerald
2025-11-05
Kursziel
$38
Neutral
Jefferies
Kaufen
$42
2025-11-05
Jefferies
2025-11-05
Kursziel
$42
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Rigel Pharmaceuticals Inc (RIGL) beträgt 9.50, verglichen mit dem 5-Jahres-Durchschnitt von -0.93.
Alphio-AI-Kursszenarien für RIGL
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die RIGL halten
Event-Zeitleiste
News
9.010-19PRnewswireRigel Pharmaceuticals Presents GAVRETO Data at ESMO Congress
5.010-02NewsfilterRigel Pharmaceuticals Grants Restricted Stock Units to Employees
1.009-02PRnewswireRigel Pharmaceuticals CFO to Participate in Investor Conferences
5.008-13PRnewswireRigel Launches First FDA-Approved PROTAC Treatment for Breast Cancer
2.008-12NASDAQ.COMRigel (RIGL) Q2 2026 Earnings Call Transcript
RIGL FAQ – beantwortet von Alphio AI
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Rigel Pharmaceuticals Inc is a good buy right now due to its current price of $48.13, which is significantly below the analyst price target of $83. The company has shown robust growth with a 62.71% increase over the past year and a strong gross margin of 89.17% in Q2 2026. The main risk is the recent earnings surprise of -3.3%, which may affect short-term sentiment.
3 analysts cover RIGL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 52.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.